BAYpress January 2016

 

WuXi News

Over 1,100 Executives Signed-up for WuXi Global Forum during J.P. Morgan Conference

WuXi Healthcare Ventures Joins Financing Round for Twist Bioscience

Dr. Ge Li Receives Executive of the Year Award from SCRIP

WuXi and MedImmune Form a Strategic Alliance to Develop Innovative Biologics in China for AstraZeneca

WuXi Plans $120M Investment in New Integrated Biologics Solution Center to Expedite Biologics Development from Ideas to Clinic

Innovation That Matters

Combatting the Hep B Virus: An Interview with George Hartman, Novira Therapeutics 
Perspectives

Combining Service and Investment: An Interview with Wei Li, Co-Founder of WuXi Healthcare Ventures

Developing a Novel ADC for Global Market via Innovative Three-Party Collaboration: An Interview with Jiawen Han, VP of WuXi Biologics
In This Issue
Industry Beats

Top 20 Life Science Start-ups to Watch in the U.S. (Source: Biospace)DNAnexus In Real Life: Tackling Precision Medicine Through Real-Time, Multi-Institution Cancer Collaboration (Source: DNAnexus)Adicet Bio Raises $51M, Makes Acquisition, as it Works on Cancer Therapy (Source: Silicon Valley Business Journal)Iconic Therapeutics Raises $40M for Eye Disease R&D (Source: Iconic Therapeutics)Kodiak Sciences Closes Series B Financing to Fuel Retina Pipeline (Source: Kodiak Sciences)

MedImmune and UCSF Announce Seven-Project Partnership (Source: GEN)

Dementia Discovery Fund Chooses Alector for First Investment – San Francisco-based Alector’s Research Focuses on Eradication of Brain Plaque by Immune System (Source: WSJ)

Oracle Sets Sights on Genetic Testing with New Precision Medicine Business (Source: Biospace)

Cortexyme Raises $15M Series A to Advance Development of Novel Therapeutics and Diagnostics for Alzheimer’s Disease (Source: Cortexyme)

Solstice Biologics Raises $4M (Source: Biospace)

University of California Investing $250M in Start-ups (Source: TechCrunch)

FDA Approvals & Designations

Upcoming Events

February 25-26, 2016
CLSA
South San Francisco, CA
March 6-11, 2016
San Francisco, CA

Please feel free to send us your company news and events.  We would be delighted to share it with our Bay Area community. 
Follow us on TwitterView our profile on LinkedIn

BAYpress November 2015

WuXi News

Gilead Sciences and WuXi Partner for a Dedicated Analytical and Stability Testing Facility

WuXi and Lilly Collaborate to Develop Novel Therapeutics in China

WuXi Receives 2015 Asian CRO Company of the Year Award from Frost & Sullivan

Congratulations to Novira Therapeutics for its Acquisition Agreement with Johnson & Johnson

Cancer, Meet the Alamo: San Antonio Enlists WuXi NextCODE to Speed Unparalleled Open-access Cancer Genome Project 

Sidra Selects WuXi NextCODE to Power Population Genomics and Precision Medicine in Qatar

WuXi Launches Mobile OncoWuXi, the World’s First App for Accessing Oncology Services

 Read full article here

Dr. Peter Schultz, CEO of The Scripps Research Institute, Visits WuXi Headquarters in Shanghai
Perspectives

Prospects for Cell and Gene Therapy: An Interview with Alan Moore, Vice President of Strategic Accounts and Cell Manufacturing 
In This Issue
Industry Beats

Breakout Labs Introduces New Portfolio Companies: nanoGriptech, Maxterial, C2Sense and CyteGen (Source: Breakout Labs)

Google Life Science and The American Heart Association Announce Collaboration to Change Trajectory of Heart Disease (Source: American Heart Association)

AstraZeneca Strengthens Cardiovascular and Metabolic Disease Portfolio with Acquisition of ZS Pharma (Source: AstraZeneca)

Portola Rolls Toward Approval for its Breakthrough Anticoagulant Antidote (Source: FierceBiotech)

Desktop Genetics Partners with Transcriptic (Source: Transcriptic)

Ginkgo Bioworks To Purchase 100 Million Base Pairs of Synthetic DNA from Twist Bioscience to Meet Growing Customer Demand for Biological Manufacturing (Source: Twist Bioscience)

Andreessen Horowitz Launches $200 Million Biotech Software Led By New Partner Vijay Pande (Source: Forbes)

Atreca Gets $56M from Gates Foundation and GSK to Advance Novel Cancer
Immunotherapies (Source: Atreca)

KaloBios Appoints Martin Shkreli CEO and Announces New Financing  (Source: KalosBio)

Threshold Pharmaceuticals Enters into Co-promotion Agreement for Evofosfamide with Merck (Source: Threshold)

FDA Approvals & Designations

Upcoming Events

December 2-3, 2015
San Jose Convention Center
 
December 2-3, 2015
Napa, CA
 
December 10, 2015
Amgen, South San Francisco
 
January 11, 2015
San Francisco, CA
 
January 11, 2015
JP Morgan Healthcare Conference 2016
San Francisco, CA

 

Forward this email

This email was sent to by communications@wuxiapptec.com |

 

WuXi AppTec | 953 Indiana St | San Francisco | CA | 94158

 

 

ILpress November 2015

UPCOMING: WuXi Representatives Visit Israel for EFMC-ASMC’15

 

 

Members of WuXi’s small molecule drug discovery platform (International Discovery Service Unit – IDSU) will be attending the EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry from November 15-18 to meet with Israeli clients and colleagues. WuXi brings world class capability and capacity through its open access platform so that anyone and any company can discover and develop healthcare products to benefit patients.
“Our team looks forward to fostering the small molecule innovation of Israeli entrepreneurs and to helping advance the world class science found in Israel” says Richard Soll, Senior VP, IDSU.
“I look forward to catching up with current and prospective clients face-to-face, and continuing to find ways to support and build our partnerships in this exciting discovery hub” says David Madge, IDSU’s Program Director.
Please contact Dana Yarden, Executive Director of Business Development, Israel for further details on WuXi’s services and IDSU’s trip to Israel.

 

 

Perspectives

Prospects for U.S. and Israel Cell and Gene Therapy: An Interview with Alan Moore, Vice President of Strategic Accounts and Cell Manufacturing 
WuXi News

WuXi and Lilly Collaborate to Develop Novel Therapeutics in China

Congratulations to Novira Therapeutics for its Acquisition Agreement with Johnson & Johnson

Cancer, Meet the Alamo: San Antonio Enlists WuXi NextCODE to Speed Unparalleled Open-access Cancer Genome Project 

Gilead Sciences and WuXi Partner for a Dedicated Analytical and Stability Testing Facility

WuXi Launches Medical Device Testing Services in China

Read full article here

WuXi Receives 2015 Asian CRO Company of the Year Award from Frost & Sullivan

Sidra Selects WuXi NextCODE to Power Population Genomics and Precision Medicine in Qatar

WuXi Launches Mobile OncoWuXi, the World’s First App for Accessing Oncology Services

 Read full article here

Dr. Peter Schultz, CEO of The Scripps Research Institute, Visits WuXi Headquarters in Shanghai
In This Issue
Industry Beats

FDA Approvals & Designations

Upcoming Events

November 23, 2015
TechnoSTAT

 

December 2, 2015
IBM Israel, Tel Aviv
 
December 8, 2015
Hilton Hotel, Tel Aviv
 
December 13- 15, 2015
Intercontinental David, Tel Aviv
 
December 14-17, 2015
Tel Aviv University

 

BAYpress September 2015

WuXi News

WuXi NextCODE in Bloomberg on Ending a 30-year Diagnostic Odyssey in 3 Weeks

WuXi NextCODE Featured in Nature as the Innovative Engine of Population-scale Precision Medicine at Genomics England and Beyond 

WuXi Receives 2015 Open-Access R&D Technology Leadership Award from Frost & Sullivan

WuXi NextCODE and Fudan Children’s Hospital Partner to Lead Whole Genome Diagnostics for Rare Diseases in China 

WuXi’s STA Subsidiary Receives First Approval from Japanese Regulatory Authorities

WuXi to Be Exclusive Supplier of Laboratory Testing Services to Lee’s Pharm

WuXi and TruTag Technology Advances Edible On-Dose Authentication Solution for Pharmaceuticals 
Perspectives

An Interview with Dr. Steve Yang, EVP and COO of WuXi AppTec and the New Head of IDSU

Meet WuXi’s Israel Partner: An Interview with Ran Nussbaum, Co-Founder and Managing Partner of Pontifax
In This Issue:
Industry Beats

 

 

 

 

 

 

Penumbra, Inc. Announces Pricing of Initial Public Offering (Source: Penumbra)

Versant Ventures Broadens Geographic Footprint with Highline Therapeutics (Source: Versant Ventures)

FDA Approvals & Designations

Upcoming Events

September 30, 2015
Online
 
October 13, 2015
CLSA, South San Francisco
 
October 27, 2015
California Academy of Sciences
 
October 27-28, 2015
Santa Clara Convention Center
November 3-4, 2015
Hyatt Regency San Francisco Airport
WuXi AppTec
953 Indiana Street
San Francisco, CA 94107

Follow us on TwitterView our profile on LinkedIn

 

IDSUpress August 2015 Newsletter

 
 

Header
---

Welcome Message from Steve Yang

Welcome to the inaugural IDSU newsletter!

As the new head of the International Discovery Services Unit (IDSU), I am proud to introduce our quarterly newsletter, bringing you the latest in medicinal chemistry and small molecule news, research, and events.

For over a decade, WuXi AppTec has built an open access capability and technology platform with a broad and integrated portfolio of services throughout the drug R&D process to enable more efficient and cost-effective research that delivers innovative medicines and treatments to patients.

IDSU is a global synthetic and medicinal chemistry solutions platform that fosters strong collaboration between pharmaceutical and biotech companies, research institutes, and innovation hubs to provide comprehensive solutions to drug discovery challenges in our industry. Our global team leverages their peer-recognized chemistry and medchem expertise and WuXi’s best-in-class fully integrated drug discovery and development platform to seamlessly progress programs from target through to preclinical candidate selection and beyond. Over the last several years, IDSU’s integrated discovery platform delivered more than 20 PCCs (Preclinical Candidates). In 2014, IDSU’s medicinal chemistry support delivered over 70,000 compounds to 100+ clients worldwide. 

We hope to continue this growth and further engage with the clients and life science communities we serve.

In the spirit of growth and collaboration, we hope you find value in this community newsletter.

Steve Yang
Head of IDSU

---

Meet IDSU Leadership

---
An Interview with the New Head of IDSU: Dr. Steve Yang, Executive Vice President and Chief Operating Officer of WuXi AppTec
---

Innovation That Matters: Albert J. Robichaud, CSO of SAGE Therapeutics

---
---

IDSU Collaborator Publications

---
---

Industry News

---
---

In Case You Missed It

---

Medicinal Chemistry

Synthetic

---

Upcoming Events

---

August 9-12, 2015
Drug Discovery Re-Invented Conference 2015
Ascot, UK

August 12-13, 2015
Cannacord Genuity Annual Growth Conference
Boston, MA

September 2-3, 2015
Drug Discovery 2015
Telford, UK

September 10, 2015
BioCentury NewsMakers
New York, NY

September 10-11, 2015
8th CNS Partnering & Deal-Making
Philadelphia, PA

September 14-16, 2015
Frontiers in Medicinal Chemistry
Antwerp, Belgium

September 15-17, 2015
BioPharm America
Boston, MA

September 29-30, 2015
2nd BioEQ 2015 Summit
Philadelphia, PA

---
---